Summary We performed subdermal injection of 99mTc-labelled albumin combined with subareolar (SA) injection of blue dye to axillary lymphatic mapping and sentinel lymph node biopsy (SLNB) in patients with multifocal and multicentric breast cancer to evaluate the feasibility and accuracy of this technique. A retrospective analysis of our experience on 235 SLNB showed that 30(12.7%) had multiple cancer (MC) on final pathologic examination and was considered in relation to the aim of the study. Mean age was 57.19 years (range 24–90). Mean number of SLNs identified was 1.93 (range 1–5). Mean number of axillary LNs examined was 18.10 (range 12–27). Overall successful identification was 100% with a false negative (FN) rate of 6.25%. Overall accuracy of lymphatic mapping and sensitivity was 96.6% and 93.7%, respectively. SLNB using the SA injection technique may be an alternative to complete axillary dissection in patients with multiple breast cancers and a clinically negative axilla.
Sentinel lymph node biopsy in multiple breast cancer using subareolar injection of the tracer
GIARDINA, Carmela;INGRAVALLO, GIUSEPPE;RUBINI, Giuseppe;
2007-01-01
Abstract
Summary We performed subdermal injection of 99mTc-labelled albumin combined with subareolar (SA) injection of blue dye to axillary lymphatic mapping and sentinel lymph node biopsy (SLNB) in patients with multifocal and multicentric breast cancer to evaluate the feasibility and accuracy of this technique. A retrospective analysis of our experience on 235 SLNB showed that 30(12.7%) had multiple cancer (MC) on final pathologic examination and was considered in relation to the aim of the study. Mean age was 57.19 years (range 24–90). Mean number of SLNs identified was 1.93 (range 1–5). Mean number of axillary LNs examined was 18.10 (range 12–27). Overall successful identification was 100% with a false negative (FN) rate of 6.25%. Overall accuracy of lymphatic mapping and sensitivity was 96.6% and 93.7%, respectively. SLNB using the SA injection technique may be an alternative to complete axillary dissection in patients with multiple breast cancers and a clinically negative axilla.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.